Mass General Brigham to conduct largest layoffs in its history

MGB said the layoffs were necessary to get ahead of an anticipated budget shortfall of $250 million over the next two years.

By Susanna Vogel • Feb. 11, 2025

Former FDA head Gottlieb calls for less regulation of certain AI tools

Gottlieb, who led the agency during the first Trump presidency, supports a reversion to an earlier interpretation of the 21st Century Cures Act.

By Elise Reuter • Feb. 11, 2025

Explore the Trendline➔

Medical device safety in spotlight after high profile recalls

From Philips’ massive recall of respiratory devices to ongoing health risks with breast implants, medical devices tied to patient harm have put a focus on product safety.

By MedTech Dive staff

M&A and a separation take center stage in latest earnings season

BD announced it would split from its biosciences and diagnostics unit, while Zimmer Biomet updated investors on its $1.1 billion buy of Paragon 28.

By Susan Kelly • Feb. 10, 2025

FDA posts early alert about BD device linked to 30 injuries, 4 deaths

The alert was posted one day after BD sent customers a letter warning about the risk of atherectomy catheters breaking.

By Nick Paul Taylor • Feb. 10, 2025

Thermo Fisher lays off another 300 workers in Massachusetts

Job cuts in Cambridge and Plainville are the second workforce reduction planned for the facilities in the past three months.

By Susan Kelly • Feb. 7, 2025

BD plans split from life science business to fuel medtech investment

CEO Tom Polen said BD will “double down on shifting our portfolio, both organically and inorganically through tuck-in M&A, into higher-growth, high-margin accretive growth spaces.”

By Nick Paul Taylor • Feb. 7, 2025

Globus to buy Nevro for $250M

Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale and orthopedic relationships.

By Elise Reuter • Feb. 6, 2025

Zimmer touts ASC opportunity with Paragon 28 purchase

With the $1.1 billion acquisition, Zimmer Biomet expects its sports medicine, extremities and trauma segment will outpace hips and knees.

By Elise Reuter • Feb. 6, 2025

Medtronic’s Orleigh Bogle on changing the culture of surgical training

Bogle, Medtronic’s head of medical affairs for digital surgery, also discussed the company’s plans to train surgeons for its Hugo surgical robot.

By Elise Reuter • Feb. 6, 2025

AHA joins call for Trump to exempt devices from import tariffs

Disruption to the supply of devices from China would curtail hospitals' ability to perform life-saving surgeries and protect patients and healthcare workers from contagion, the group warned.

By Nick Paul Taylor • Feb. 6, 2025

Pulse Biosciences names new CFO, continuing string of C-suite changes

Pulse, which named a new CEO last month, is pitching its pulsed field ablation technology as a way to shorten procedure times.

By Nick Paul Taylor • Feb. 5, 2025

Boston Scientific closes its year of PFA on a high note

Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth quarter for the company’s electrophysiology group.

By Ricky Zipp • Feb. 5, 2025

Illumina placed on China’s unreliable entity list

Analysts said the move comes amid rising trade tensions with the U.S. and as Illumina faces stiff competition in China’s genome sequencing market.

By Susan Kelly • Feb. 5, 2025

Medtronic recall of brain fluid drainage systems linked to 15 injuries

The company will keep the systems on the market but is asking providers to check devices for visible cracks and return affected devices.

By Nick Paul Taylor • Feb. 4, 2025

RFK Jr. clears key hurdle on path to HHS secretary

A key Senate committee voted to advance Robert F. Kennedy’s nomination even after some legislators raised concerns about his previous vaccine stances and confusion surrounding programs like Medicare and Medicaid.

By Sydney Halleman , Delilah Alvarado , Jonathan Gardner • Feb. 4, 2025

FDA labels recall of discontinued Olympus endoscope part as Class I

The update comes about six weeks after an early alert flagged reports of 120 injuries and one death linked to reprocessing of the device.

By Susan Kelly • Feb. 3, 2025

Advamed pushes for medical device exemption from Trump tariffs

CEO Scott Whitaker said “an exemption was provided for most medical devices during President Trump’s first term with respect to the tariffs on China, and we are advocating for a similar approach.”

By Susan Kelly • Feb. 3, 2025

Baxter CEO José Almeida retires

Brent Shafer, Baxter’s lead independent director, will serve as interim CEO. The company also promoted Heather Knight to chief operating officer.

By Elise Reuter • Feb. 3, 2025

Trump issues tariffs on Canada, Mexico and China

The president ordered an additional 10% duty on goods from China and 25% tariffs on imports from Canada and Mexico, though Canadian energy resources will face a lower rate.

By Philip Neuffer • Updated Feb. 1, 2025

Troy Tazbaz, CDRH digital health leader, resigns

Tazbaz was director of the FDA’s Digital Health Center of Excellence for two years, leading key policies on artificial intelligence and software as a medical device.

By Elise Reuter • Jan. 31, 2025

Top medtech trends in 2025: New products and M&A are bright spots, but Trump brings uncertainty

Experts highlighted surgical robotics, artificial intelligence and M&A as top trends this year. However, the Trump administration could create challenges for the industry.

By Ricky Zipp • Jan. 31, 2025

Beta Bionics raises $204M in IPO

The diabetes tech firm began trading this week and was valued at $966.2 million as of Thursday.

By Elise Reuter • Jan. 31, 2025

FDA warns about patient monitor cybersecurity vulnerabilities

Vulnerabilities in certain Contec and Epsimed patient monitors can allow people to gain access and potentially manipulate the devices, the FDA warned.

By Nick Paul Taylor • Jan. 31, 2025

Getinge exits surgical perfusion, creating opportunity for Livanova

Getinge CEO Mattias Perjos said surgical perfusion has “been a struggling category” since an FDA consent decree forced the company off the U.S. market in 2015.

By Nick Paul Taylor • Jan. 30, 2025

White House rescinds memo pausing federal funding following pushback

The Office of Management and Budget rolled back a memo halting federal funding that caused widespread confusion and alarm. But “this is NOT a rescission of the federal funding freeze,” Trump’s top press secretary said.

By Rebecca Pifer • Jan. 29, 2025